Axsome Therapeutics, Inc.
37
8
9
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
8.1%
3 terminated/withdrawn out of 37 trials
87.5%
+1.0% vs industry average
70%
26 trials in Phase 3/4
57%
12 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (37)
Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder
Role: collaborator
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Role: lead
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
Role: lead
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
Role: lead
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Role: lead
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
Role: lead
Initiating Early Control of Migraine Pain and Associated Symptoms
Role: lead
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
Role: lead
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Role: lead
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
Role: lead
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
Role: lead
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
Role: lead
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Role: lead
Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
Role: lead
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Role: lead
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)
Role: lead
Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder
Role: collaborator
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Role: collaborator
Solriamfetol and CBT-I in Patients With Insomnia Disorder
Role: collaborator
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
Role: lead